These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 14509689)

  • 1. Autonomic side effects of botulinum toxin type B therapy.
    Dressler D; Benecke R
    Adv Neurol; 2004; 94():315-20. PubMed ID: 14509689
    [No Abstract]   [Full Text] [Related]  

  • 2. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial.
    Tintner R; Gross R; Winzer UF; Smalky KA; Jankovic J
    Neurology; 2005 Sep; 65(5):765-7. PubMed ID: 16157918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dystonia and headaches: clinical features and response to botulinum toxin therapy.
    Galvez-Jimenez N; Lampuri C; Patiño-Picirrillo R; Hargreave MJ; Hanson MR
    Adv Neurol; 2004; 94():321-8. PubMed ID: 14509690
    [No Abstract]   [Full Text] [Related]  

  • 5. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of effectiveness of botulinum toxin type B in the treatment of cervical dystonia.
    Lew MF
    Adv Neurol; 2004; 94():211-5. PubMed ID: 14509675
    [No Abstract]   [Full Text] [Related]  

  • 7. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.
    Dressler D; Benecke R
    Eur Neurol; 2003; 49(1):34-8. PubMed ID: 12464716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months.
    Frasson E; Brigo F; Acler M; Didonè G; Vicentini S; Bertolasi L
    Arch Dermatol; 2011 Jan; 147(1):122-3. PubMed ID: 21242408
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.
    Jankovic J; Hunter C; Dolimbek BZ; Dolimbek GS; Adler CH; Brashear A; Comella CL; Gordon M; Riley DE; Sethi K; Singer C; Stacy M; Tarsy D; Atassi MZ
    Neurology; 2006 Dec; 67(12):2233-5. PubMed ID: 17190952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis.
    Baumann LS; Halem ML
    Arch Dermatol; 2003 Feb; 139(2):226-7. PubMed ID: 12588237
    [No Abstract]   [Full Text] [Related]  

  • 11. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
    Dressler D; Bigalke H
    J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin therapy for cervical dystonia.
    Jankovic J
    Neurotox Res; 2006 Apr; 9(2-3):145-8. PubMed ID: 16785112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type B (Myobloc).
    Baumann L; Black L
    Dermatol Surg; 2003 May; 29(5):496-500; discussion 500. PubMed ID: 12752517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply: Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial.
    Mueller J
    Mov Disord; 2009 May; 24(7):1098-9; author reply 1100. PubMed ID: 18942082
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of botulinum toxin a and B on vegetative cardiac innervation].
    Meichsner M; Reichel G
    Fortschr Neurol Psychiatr; 2005 Jul; 73(7):409-14. PubMed ID: 16012920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding use of botulinum toxin.
    Bhidayasiri R; Truong DD
    J Neurol Sci; 2005 Aug; 235(1-2):1-9. PubMed ID: 15990116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term effects of botulinum toxin treatment].
    Krystkowiak P
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S86-8. PubMed ID: 19576491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients.
    Cullis PA; O'Brien CF; Truong DD; Koller M; Villegas TP; Wallace JD
    Adv Neurol; 1998; 78():227-30. PubMed ID: 9750919
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasticity of static graviceptive function in patients with cervical dystonia.
    Platho-Elwischger K; Kranz G; Sycha T; Dunkler D; Rommer P; Mueller C; Auff E; Wiest G
    J Neurol Sci; 2017 Feb; 373():230-235. PubMed ID: 28131194
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.